Vanguard Personalized Indexing Management LLC Sells 7,433 Shares of Rocket Pharmaceuticals, Inc. $RCKT

Vanguard Personalized Indexing Management LLC lessened its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 37.6% in the second quarter, according to its most recent filing with the SEC. The firm owned 12,351 shares of the biotechnology company’s stock after selling 7,433 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Rocket Pharmaceuticals were worth $30,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Farther Finance Advisors LLC lifted its holdings in Rocket Pharmaceuticals by 7,818.1% during the second quarter. Farther Finance Advisors LLC now owns 13,540 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 13,369 shares in the last quarter. PFG Investments LLC lifted its holdings in shares of Rocket Pharmaceuticals by 35.1% during the 2nd quarter. PFG Investments LLC now owns 18,100 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 4,700 shares in the last quarter. 111 Capital bought a new position in shares of Rocket Pharmaceuticals during the 2nd quarter valued at about $55,000. Signaturefd LLC lifted its holdings in shares of Rocket Pharmaceuticals by 83.6% during the 1st quarter. Signaturefd LLC now owns 9,024 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 4,108 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in Rocket Pharmaceuticals in the first quarter valued at approximately $69,000. 98.39% of the stock is currently owned by institutional investors.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ:RCKT opened at $3.94 on Tuesday. The company’s 50 day simple moving average is $3.42 and its 200 day simple moving average is $3.97. The stock has a market capitalization of $425.14 million, a price-to-earnings ratio of -1.57 and a beta of 0.60. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.39 and a quick ratio of 6.39. Rocket Pharmaceuticals, Inc. has a 1 year low of $2.19 and a 1 year high of $18.17.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). During the same period in the previous year, the company earned ($0.74) EPS. As a group, research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Chardan Capital restated a “buy” rating and issued a $11.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, October 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, October 8th. Needham & Company LLC restated a “hold” rating on shares of Rocket Pharmaceuticals in a research note on Thursday, July 24th. Leerink Partners cut their price objective on shares of Rocket Pharmaceuticals from $9.00 to $7.00 and set a “market perform” rating on the stock in a research report on Friday, October 3rd. Finally, Canaccord Genuity Group cut their price objective on shares of Rocket Pharmaceuticals from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, July 25th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $16.67.

Insiders Place Their Bets

In related news, insider John Militello sold 28,918 shares of the stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $3.96, for a total value of $114,515.28. Following the transaction, the insider directly owned 67,006 shares in the company, valued at $265,343.76. This trade represents a 30.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jonathan David Schwartz sold 11,161 shares of the firm’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $3.02, for a total transaction of $33,706.22. Following the completion of the transaction, the insider directly owned 224,094 shares in the company, valued at approximately $676,763.88. The trade was a 4.74% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,368 shares of company stock worth $221,675 in the last quarter. 24.76% of the stock is currently owned by company insiders.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.